[ 1 ] European Association for The Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection[J]. J Hepatol, 2012, 57(1): 167-185.
[ 3 ] Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update[J]. Hepatol Int, 2012, 6(3): 531-561.
[ 6 ] Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States[J]. N Engl J Med, 1999, 341(17): 1256-1263.
[7]
[ 7 ] Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy[J]. Hepatology, 2009, 49(Suppl 5): S174-S184.
[8]
[ 8 ] Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B[J]. Gastroenterology, 2009, 136(2): 486-495.
[9]
[ 9 ] Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J]. N Engl J Med, 2003, 348(9): 808-816.
[10]
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B[J]. N Engl J Med, 2003, 348(9): 800-807.
[11]
Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J]. Hepatology, 2008, 48(3): 750-758.
[12]
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years[J]. Gastroenterology, 2006, 131(6): 1743-1751.
[13]
Keeffe EB, Marcellin P. New and emerging treatment of chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2007, 5(3): 285-294.
[14]
Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na？ve patients is rare through 5 years of therapy[J]. Hepatology, 2009, 49(5): 1503-1514.
[15]
Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B[J]. N Engl J Med, 2006, 354(10): 1011-1020.
Kwon JH, Jang JW, Lee S, et al. Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B[J]. J Viral Hepat, 2012, 19(2): e41-e47.
[18]
Zhang X, Lin SM, Ye F, et al. An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients[J]. J Viral Hepat, 2011, 18(7): e184-e190.
Jin YJ, Shim JH, Chung YH, et al. HLA-DRB1*010101 allele is closely associated with poor virological response to lamivudine therapy in patients with chronic hepatitis B[J]. Digestion, 2011, 84(Suppl 1): 35-42.
[21]
Wu JF, Chen CH, Hsieh RP, et al. HLA typing associated with hepatitis B E antigen seroconversion in children with chronic hepatitis B virus infection: a long-term prospective sibling cohort study in Taiwan[J]. J Pediatr, 2006, 148(5): 647-651.
[22]
Wu JF, Wu TC, Chen CH, et al. Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion[J]. Gastroenterology, 2010, 138(1): 165-172.
[23]
Cheong JY, Cho SW, Oh B, et al. Association of interleukin-18 gene polymorphisms with hepatitis B virus clearance[J]. Dig Dis Sci, 2010, 55(4): 1113-1119.
[24]
Stoop JN, Woltman AM, Biesta PJ, et al. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response[J]. Hepatology, 2007, 46(3): 699-705.
[25]
Wang S, Huang D, Sun S, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa[J]. Virol J, 2011, 20(8): 28.
[26]
Ren S, Yu H, Zhang H, et al. Polymorphisms of interferon-inducible genes OAS associated with interferon-α treatment response in chronic HBV infection[J]. Antiviral Res, 2011, 89(3): 232-237.
[27]
Mizokami M. Discovery of critical host factor, IL-28B, associated with response to hepatitis C virus treatment[J]. J Gastroenterol Hepatol, 2012, 27(3): 425-429.
[28]
Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B[J]. N Engl J Med, 2006, 354(10): 1001-1010.
[29]
Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine[J]. Antimicrob Agents Chemother, 2004, 48(9): 3498-3507.
[30]
Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient[J]. J Hepatol, 2007, 46(3): 531-538.
[31]
Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes[J]. J Gen Virol, 1988, 69(Pt 10): 2575-2583.
[32]
Norder H, Couroucé AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes[J]. Virology, 1994, 198(2): 489-503.
[33]
Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness[J]. J Gen Virol, 2000, 81(Pt 1): 67-74.
[34]
Cooksley WG. Do we need to determine viral genotype in treating chronic hepatitis B[J]. J Viral Hepat, 2010, 17(9): 601-610.
[35]
Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C[J]. Gastroenterology, 2002, 122(7): 1756-1762.
[36]
Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline[J]. J Hepatol, 2005, 43(3): 411-417.
[37]
Hou J, Schilling R, Janssen HL, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance[J]. J Med Virol, 2007, 79(8): 1055-1063.
[38]
lloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J]. Gastroenterology, 2006, 130(3): 678-686.
[39]
Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach[J]. Gastroenterology, 2008, 134(2): 405-415.
[40]
Chou YC, Yu MW, Wu CF, et al. Temporal relationship between hepatitis B virus enhancer Ⅱ/basal core promoter sequence variation and risk of hepatocellular carcinoma[J]. Gut, 2008, 57(1): 91-97.
[41]
Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection[J]. Antiviral Res, 2004, 64(1): 1-15.
[42]
Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J]. Gastroenterology, 2004, 126(7): 1750-1758.
[43]
Thursz M, Yee L, Khakoo S. Understanding the host genetics of chronic hepatitis B and C[J]. Semin Liver Dis, 2011, 31(2): 115-127.
[44]
Fabris C, Falleti E, Cussigh A, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC[J]. J Hepatol, 2011, 54(4): 716-722.
[45]
Lampertico P, Vigan？ M, Cheroni C, et al. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B[J]. Hepatology, 2013, 57(3): 890-896.
